Ocular Therapeutix公司 OCUL 深 沪
等待开盘 09-02 09:30:00 美东时间
10.57
+0.080
+0.76%
华盛通- 最 高10.66
- 今 开10.42
- 成交量 157.83万股
- 最 低 10.32
- 昨 收 10.49
- 总市值 23.21亿
- 52周最高 16.44
- 市盈率 静 --
- 换手率 0.72%
- 52周最低 6.2301
- 委 比 79.26%
- 总股本 2.20亿
- 历史最高 44.19
- 量 比 1.02
- 振 幅 3.24%
- 历史最低 1.995
- 每 手 1
- 风险率 1.71%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Why Is Ocular Therapeutix Stock Gaining Monday?
Ocular Therapeutix Inc. (NASDAQ:OCUL) stock is trading higher on Monday as the stock reacts to underwhelming data from its rival, EyePoint Inc. (NASDAQ:EYPT). EyePoint released topline results from its pivotal Phase 3 LUGANO trial. The study evaluated Duravyu for wet age-related macular degeneration...
08-18 01:48
H World Group Posts Upbeat Q2 Results, Joins Almonty Industries, Diana Shipping And Other Big Stocks Moving Higher On Monday
U.S. stocks were lower, with the Dow Jones index falling over 100 points on Monday. Shares of H World Group Ltd (NASDAQ:HTHT) rose sharply after the company reported better-than-expected second-quarter financial results and raised its FY26 sales guidance. H World Group reported quarterly earnings of...
08-17 21:51
财报速睇 | Ocular Therapeutix公司 2026财年Q2营收0.13亿美元，同比增长0.1%；归母净利润亏损0.79亿美元，同比亏损扩大16.1%
华盛资讯8月4日讯，Ocular Therapeutix公司公布2026财年Q2业绩，公司Q2营收0.13亿美元，同比增长0.1%，归母净利润亏损0.79亿美元，同比亏损扩大16.1%。
08-04 01:40
Ocular Therapeutix Q2 EPS $(0.35) Beats $(0.40) Estimate, Sales $13.475M Beat $13.199M Estimate
Ocular Therapeutix (NASDAQ:OCUL) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.40) by 10.26 percent. This is a 10.26 percent increase over losses of $(0.39) per share from the same period last year. The company reported quarterly sales of $13.475 mil...
08-03 19:06
OCUL’s OTX-TKI Extension Study: Long-Term Safety Data Could Shape Wet AMD Market
Ocular Therapeutix Inc ($OCUL) announced an update on their ongoing clinical st...
07-02 00:31
美股大行评级 | 潜在涨幅135.66%！Ocular Therapeutix获Chardan Capital升目标价至23美元，维持"买入"评级
今日重点评级关注：Chardan Capital：维持Ocular Therapeutix"买入"评级，目标价从21美元升至23美元；Guggenheim：维持Amylyx Pharmaceuticals"买入"评级，目标价从30美元升至40美元
06-26 17:42
Chardan Capital Maintains Buy on Ocular Therapeutix, Raises Price Target to $23
Chardan Capital analyst Andreas Argyrides maintains Ocular Therapeutix (NASDAQ:OCUL) with a Buy and raises the price target from $21 to $23.
06-25 21:34
Ocular Therapeutix Plans Q4 2026 NDA Submission For AXPAXLI In Wet AMD Based On SOL-1 Data, Removes SOL-R Efficacy From Filing And Extends Trial Timeline To 2028
Per May 2026 Type C meeting, AXPAXLI NDA for wet AMD to be based on SOL-1 Week 52 efficacy and safety plus interim SOL-R safety data Ocular to conduct interim SOL-R safety analysis in 4Q 2026 to reach >300 patients of safety data across SOL-1 and SOL-R, in alignment with FDA requirements Complete AX...
06-17 20:46
